Literature DB >> 32378728

Knockdown of ADAMDEC1 inhibits the progression of glioma in vitro.

Xueliang Liu1,2, Hao Huang1, Xuehan Li3, Xiaomei Zheng4, Chong Zhou5, Bin Xue6, Jimin He7, Ye Zhang8, Liang Liu1,9,10.   

Abstract

BACKGROUND: Glioma is one of the most lethal malignant tumors all over the world. The prognosis of patients with high‑grade glioma remains very poor. Therefore, it is urgent to find a novel strategy for the treatment of glioma. It has been reported that ADAMDEC1 could regulate the progression of multiple diseases, including cancers. However, the role of ADAMDEC1 during the tumorigenesis of glioma remains largely unknown. Methods, Gene expression of ADAMDEC1 in glioma tissues or in cells was detected by qRT-PCR. Western blot was performed to measure the protein expressions of p53, active caspase3, active caspase9, CDK2 and Cyclin A in glioma cells. Cell proliferation was detected by CCK-8 assay. Cell apoptosis or cycle was tested by flow cytometry. Transwell was used to test the invasion of glioma cells.
RESULTS: The expression of ADAMDEC1 in glioma tissues or cells was significantly upregulated. In addition, downregulation of ADAMDEC1 notably inhibited the proliferation and induced apoptosis of glioma cells through upregulation of active caspase 3 and active caspase 9. Besides, silencing of ADAMDEC1 obviously induced G1 arrest in glioma cells via modulation of cell cycle-related proteins. Finally, knockdown of ADAMDEC1 significantly inhibited the migration and invasion of glioma cells. In contrast, overexpression of ADAMDEC1 promoted cell proliferation, migration and invasion of glioma cells.
CONCLUSION: Downregulation of ADAMDEC1 could significantly inhibit the tumorigenesis of glioma in vitro, which may serve as a novel target for the treatment of glioma.

Entities:  

Year:  2020        PMID: 32378728     DOI: 10.14670/HH-18-227

Source DB:  PubMed          Journal:  Histol Histopathol        ISSN: 0213-3911            Impact factor:   2.303


  4 in total

1.  Upregulation of ADAMDEC1 correlates with tumor progression and predicts poor prognosis in non-small cell lung cancer (NSCLC) via the PI3K/AKT pathway.

Authors:  Weiliang Zhu; Lin Shi; Yuxin Gong; Lin Zhuo; Siyun Wang; Shaobing Chen; Bei Zhang; Bin Ke
Journal:  Thorac Cancer       Date:  2022-02-17       Impact factor: 3.500

2.  Potential biomarkers that discriminate rheumatoid arthritis and osteoarthritis based on the analysis and validation of datasets.

Authors:  Le Kang; Chengqian Dai; Lihong Wang; Xinling Pan
Journal:  BMC Musculoskelet Disord       Date:  2022-04-04       Impact factor: 2.362

3.  Diagnosis and Prediction of Endometrial Carcinoma Using Machine Learning and Artificial Neural Networks Based on Public Databases.

Authors:  Dongli Zhao; Zhe Zhang; Zhonghuang Wang; Zhenglin Du; Meng Wu; Tingting Zhang; Jialu Zhou; Wenming Zhao; Yuanguang Meng
Journal:  Genes (Basel)       Date:  2022-05-24       Impact factor: 4.141

4.  ADAMDEC1 accelerates GBM progression via activation of the MMP2-related pathway.

Authors:  Huimin Qi; Ping Wang; Hongliang Sun; Xiaohan Li; Xinwei Hao; Wenxiu Tian; Liting Yu; Jiajian Tang; Junhong Dong; Hongmei Wang
Journal:  Front Oncol       Date:  2022-09-12       Impact factor: 5.738

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.